Three clinical studies presented at AOFAS 2026 show sustained outcomes for Treace's bunion correction systems, including a milestone five-year dataset.

Treace Medical Concepts, Inc. (NASDAQ:TMCI) reported five-year results from the ALIGN3D study for the Lapiplasty bunion-correction procedure. The analysis included 137 of 173 treated patients across seven U.S. sites and 13 surgeons. Radiographic recurrence was reported at 0.8% for a hallux valgus a…

Lapiplasty 3D bunion correction corrects bunions with titanium plating. Learn about candidacy, recovery, and our certified surgeon in Florida.

Reported Thursday, Jan 8 - 4:44pm EST (TheFly subscription required to read more.)

Dr. Erik Miller from Lima Memorial discusses a treatment option for those dealing with bunions.

Treace Medical Concepts (NASDAQ:TMCI), a medical technology company specializing in bunion surgery solutions, has published four-year interim results from its ALIGN3D™ multicenter prospective study in the Journal of Foot & Ankle Surgery. The study, which followed 139 of 173 patients, demonstrated strong outcomes for the Lapiplasty® Procedure.Key findings include an early return to protected weight bearing at 7.7 days, transition to athletic shoes at 6.5 weeks, and notably low recurrence rates of 0.8% using HVA>20° and 8.4% using HVA>15° at 48 months. Patient outcomes showed significant improvements, with an 81% reduction in pain and 89% improvement in walking/standing capabilities through the 48-month period.

Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology  Ortho Spine News

Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology  The Manila Times

JHVEPhoto/iStock Editorial via Getty Images Treace Medical Concepts (NASDAQ:TMCI) on Thursday announced it sued Zimmer Biomet Holdings (NYSE:ZBH), alleging that the MedTech giant infringed four patents related to its Lapiplasty 3D bunion correction technology. The lawsuit filed in a Delaware District Court seeks an injunction

Faruqi & Faruqi, a national securities law firm, is probing claims against Treace Medical following significant stock losses. Investors with losses are urged to respond.

Dr. Eric Miller from Lima Memorial talks to us about lapiplasty!

Treace Medical Concepts (NASDAQ: TMCI) presented updated clinical data for its bunion and midfoot deformity treatments at the 2025 ACFAS Conference. The company showcased results from three key studies:The ALIGN3D™ study (135 patients, 4-year follow-up) showed early weight bearing at 8.4 days and low recurrence rates of 0.8% (HVA>20°). The Mini3D™ study (75 patients, 1-year follow-up) demonstrated weight bearing at 7.9 days with 0% recurrence (HVA>20°). The MTA3D™ study (18 patients, 1-year follow-up) reported weight bearing at 7.5 days with significant improvements in both midfoot and bunion deformity correction.All studies showed significant improvements in pain and patient-reported outcomes. Additional retrospective data from 43 patients undergoing Adductoplasty® and Lapiplasty® procedures showed positive clinical results over a 17.7-month follow-up period.

Enter to win a 2-night trip for two to Dallas, TX, tickets to the Lapiplasty 3D Bunion Correction Pickleball World Championships and two pickleball paddles. Valued at $4,600.